SCHEMBL8260381

SCHEMBL8260381

CNC(=O)C(C)(C)NC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10281015 0.79
SCHEMBL19964618 0.77 EPHX1 (0.36)
SCHEMBL6283382 0.77
SCHEMBL20951516 0.75 CNR2 (0.33)
SCHEMBL8369697 0.73
SCHEMBL15616264 0.73 L3MBTL1 (0.32)
SCHEMBL179521 0.73
SCHEMBL24111566 0.73
SCHEMBL21546118 0.73 FAAH (0.37)
SCHEMBL21394691 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12024549-B2 Compound having affinity substance to soluble protein, cleavable portion and reactive group, or salt thereof AJINOMOTO CO., INC. (JP) 2024-07-02 US disclosed
WO-2023006097-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER 海创药业股份有限公司 2023-02-02 WO disclosed
EP-3431489-B1 DIPEPTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH AMYLOID FIBRIL FORMATION UNIV RAMOT (IL) 2020-12-23 EP disclosed
EP-3209664-B1 BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-06-03 EP disclosed
EP-3402785-B1 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES GRUENENTHAL GMBH (DE) 2020-02-26 EP disclosed
US-20170355707-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-12-14 US disclosed
US-9783573-B2 IAP antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2017-10-10 US disclosed
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 US disclosed
US-9630989-B2 Dipeptide analogs for treating conditions associated with amyloid fibril formation RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2017-04-25 US disclosed
US-20160235716-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC. (US) 2016-08-18 US disclosed
US-20100145036-A1 CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF MEDAREX, INC. (US) 2010-06-10 US disclosed
US-20100143368-A1 Human Antibodies That Bind Cd22 And Uses Thereof E. R. SQUIBB & SONS, L.L.C. 2010-06-10 US disclosed
US-20100093719-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. (US) 2010-04-15 US disclosed
US-20100093719-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. (US) 2010-04-15 US disclosed
US-20100092496-A1 CHEMICAL LINKERS AND CONJUGATES THEREOF MEDAREX, INC. (US) 2010-04-15 US disclosed
US-20080176844-A1 Pharmacokinetically Improved Compounds SURFACE LOGIX, INC. 2008-07-24 US disclosed
US-20080176844-A1 Pharmacokinetically Improved Compounds SURFACE LOGIX, INC. 2008-07-24 US disclosed
US-20070142380-A1 Viral Polymerase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 US disclosed
WO-2006089276-A2 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. (US) 2006-08-24 WO disclosed
WO-2006089275-A2 METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS SURFACE LOGIX, INC. (US) 2006-08-24 WO disclosed